Key points are not available for this paper at this time.
Data on the efficacy and safety of anti PD-1 antibodies in children and adolescents (CA) with melanoma are lacking. The aim of this study was to determine outcomes of CA melanoma patients receiving anti PD-1 antibodies.
Mandalà et al. (Tue,) studied this question.